socaltech.com
San Diego-based
Design Therapeutics, a biotech company which is developing small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, said it has raised $125M in its Series B funding round. The funding was led by Logos Cpaital, and also included Cormorant Asset Management, SR One, Quan Capital and WestRiver Group, plus funds and accounts managed by BlackRock, Janus Henderson Investors, RA Capital Management, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Wellington Management, Avoro Capital Advisors, Vivo Capital, and others. The company said the funding will go to advance its pipeline. Arsani William, M.D., managing partner and chief investment officer of Logos Capital, and John Schmid, industry veteran and former chief financial officer of Auspex Pharmaceuticals, have both joined the company s board with the funding.
Neurogene in tie up with university to advance gene therapy technologies New York based, Neurogene, has announced a research collaboration with the University of Edinburgh for the development of a multiple-platform approach to diseases not addressable by conventional gene therapy.
However, the partners were not willing to disclose, as of today, which diseases exactly are being targeted under this alliance.
The collaborative project combines Neurogene’s manufacturing and drug development capabilities with the University of Edinburgh’s novel platform and neurodevelopmental disease expertise.
Under the terms of the collaboration, the US company will provide financial support for Dr Stuart Cobb’s laboratory at the University of Edinburgh, in exchange for the right to license any applicable intellectual property at agreed-upon economic terms. Neurogene will be responsible for late stage preclinical and all clinical development of any products generat
Jan 19 2021, 5:55 PM
January 19 2021, 10:30 AM
January 19 2021, 5:55 PM
(Bloomberg) After a blockbuster start to the year for euro-area bond sales, a barrage of debt from the European Union risks chipping away at future demand for its member countries.
(Bloomberg) After a blockbuster start to the year for euro-area bond sales, a barrage of debt from the European Union risks chipping away at future demand for its member countries.
The bloc is due to launch its first bonds of the year in the next week, after its initial social debt sales in 2020 drew record bidding. It will follow that up in 2021 by making a start on 750 billion euros ($909 billion) in joint issuance to fund the regionâs recovery from the pandemic.